Obiltoxaximab receives marketing authorization from European Commission for the treatment of inhalation anthrax

This monoclonal antibody anthrax antitoxin is approved for use in combination with appropriate antibiotics for treatment of inhalational anthrax (IA) due to Bacillus anthracis; and for post-exposure prophylaxis of IA when alternative therapies are not available/not appropriate.

Biospace Inc.